WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Stephan Weidinger, MD, PhD

Director
Department of Dermatology and Allergy
University Hospital Schleswig-Holstein
Kiel, Germany

Disclosures

Stephan Weidinger, MD, PhD, has no relevant financial relationships.

Melinda Gooderham, MD, MSc, FRCP

Assistant Professor
Queens University
Medical Director
SKiN Centre for Dermatology
Peterborough, Ontario, Canada

Disclosures

Melinda Gooderham, MD, MSc, FRCP, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Akros Pharma Inc.; Amgen, Inc.; Apogee; Arcutis Biotherapeutics, Inc.; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Galderma Laboratories, L.P.; Incyte Corporation; Janssen; Kyowa Kirin Pharmaceutical Development, Inc.; LEO Pharma, Inc.; Novartis; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi Genzyme; Sun Pharmaceutical Industries, Ltd.; UCB; Union Therapeutics A/S
Speaker or member of speakers bureau for: AbbVie, Inc.; Amgen, Inc.; Arcutis Biotherapeutics, Inc.; Bausch Health Companies Inc.; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Galderma Laboratories, L.P.; Incyte Corporation; Janssen; LEO Pharma, Inc.; Novartis; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharmaceutical Industries, Ltd.; UCB
Research funding from: AbbVie, Inc.; Akros Pharma Inc.; Amgen, Inc.; AnaptysBio, Inc.; Apogee; Arcutis Biotherapeutics, Inc.; Aristea; Bausch Health Companies Inc.; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Dermira, Inc.; Dermavant Sciences, Inc.; Eli Lilly and Company; Galderma Laboratories, L.P.; GlaxoSmithKline; Incyte Corporation; Janssen; Kyowa Kirin Pharmaceutical Development, Inc.; LEO Pharma, Inc.; MedImmune Inc.; Meiji Seika Kaisha, Ltd.; Merck; MoonLake; Nimbus; Novartis; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi Genzyme; Sun Pharmaceutical Industries, Ltd.; Takeda; Tarus; UCB; Ventyx
Contracted researcher for: AbbVie, Inc.; Akros Pharma Inc.; Amgen, Inc.; AnaptysBio, Inc.; Apogee; Arcutis Biotherapeutics, Inc.; Aristea; Bausch Health Companies Inc.; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Dermira, Inc.; Dermavant Sciences, Inc.; Eli Lilly and Company; Galderma Laboratories, L.P.; GlaxoSmithKline; Incyte Corporation; Janssen; Kyowa Kirin Pharmaceutical Development, Inc.; LEO Pharma, Inc.; MedImmune, Inc.; Meiji Seika Kaisha, Ltd.; Merck; MoonLake; Nimbus; Novartis; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi Genzyme; Sun Pharmaceutical Industries, Ltd.; Takeda; Tarsus; UCB; Ventyx

Alan Irvine, MD

Professor of Dermatology
Trinity College Dublin
Dublin, Ireland

Disclosures

Alan Irvine, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Aslan; Connect Biopharma; Eli Lilly and Company; LEO Pharma, Inc.; Novartis; Pfizer, Inc.; RAPT Therapeutics; Regeneron Pharmaceuticals, Inc.; Sanofi; UCB
Speaker or member of speakers bureau for: AbbVie, Inc.; Almirall S.A.; Eli Lilly and Company; Janssen; Kenvue; Regeneron Pharmaceuticals, Inc.; Sanofi
Research funding from: Regeneron Pharmaceuticals, Inc.

Editor

Marinella Calle, PhD, CMPP

Medical Education Director, WebMD Global, LLC

Disclosures

Marinella Calle, PhD, CMPP, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CPD

Established and Emerging Therapies for Moderate-to-Severe Atopic Dermatitis: The Data in Context

Authors: Stephan Weidinger, MD, PhD; Melinda Gooderham, MD, MSc, FRCP; Alan Irvine, MD
CPD Released: 11/8/2023
Valid for credit through: 11/8/2024, 11:59 PM EST

Start Activity

Credits Available

Non-US Physicians - maximum of 0.50 CPD

You Are Eligible For
- Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an European audience of dermatologists, allergists, and clinical immunologists.

The goal of this activity is for learners to be better able to describe the role of interleukin (IL)-13 in moderate-to-severe AD, discuss the latest key clinical efficacy and safety data for emerging therapies to treat moderate-to-severe AD, and relate the key data to clinical practice.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Key factors influencing treatment choice for moderate-to-severe AD
- Latest clinical data on biologics for moderate-to-severe AD
Have improved competence in
- Selecting an appropriate therapy for patients with moderate-to-severe AD

Disclosures

Faculty

Stephan Weidinger, MD, PhD

Director
Department of Dermatology and Allergy
University Hospital Schleswig-Holstein
Kiel, Germany

Disclosures

Stephan Weidinger, MD, PhD, has no relevant financial relationships.

Melinda Gooderham, MD, MSc, FRCP

Assistant Professor
Queens University
Medical Director
SKiN Centre for Dermatology
Peterborough, Ontario, Canada

Disclosures

Melinda Gooderham, MD, MSc, FRCP, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Akros Pharma Inc.; Amgen, Inc.; Apogee; Arcutis Biotherapeutics, Inc.; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Galderma Laboratories, L.P.; Incyte Corporation; Janssen; Kyowa Kirin Pharmaceutical Development, Inc.; LEO Pharma, Inc.; Novartis; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi Genzyme; Sun Pharmaceutical Industries, Ltd.; UCB; Union Therapeutics A/S
Speaker or member of speakers bureau for: AbbVie, Inc.; Amgen, Inc.; Arcutis Biotherapeutics, Inc.; Bausch Health Companies Inc.; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Galderma Laboratories, L.P.; Incyte Corporation; Janssen; LEO Pharma, Inc.; Novartis; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharmaceutical Industries, Ltd.; UCB
Research funding from: AbbVie, Inc.; Akros Pharma Inc.; Amgen, Inc.; AnaptysBio, Inc.; Apogee; Arcutis Biotherapeutics, Inc.; Aristea; Bausch Health Companies Inc.; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Dermira, Inc.; Dermavant Sciences, Inc.; Eli Lilly and Company; Galderma Laboratories, L.P.; GlaxoSmithKline; Incyte Corporation; Janssen; Kyowa Kirin Pharmaceutical Development, Inc.; LEO Pharma, Inc.; MedImmune Inc.; Meiji Seika Kaisha, Ltd.; Merck; MoonLake; Nimbus; Novartis; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi Genzyme; Sun Pharmaceutical Industries, Ltd.; Takeda; Tarus; UCB; Ventyx
Contracted researcher for: AbbVie, Inc.; Akros Pharma Inc.; Amgen, Inc.; AnaptysBio, Inc.; Apogee; Arcutis Biotherapeutics, Inc.; Aristea; Bausch Health Companies Inc.; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Dermira, Inc.; Dermavant Sciences, Inc.; Eli Lilly and Company; Galderma Laboratories, L.P.; GlaxoSmithKline; Incyte Corporation; Janssen; Kyowa Kirin Pharmaceutical Development, Inc.; LEO Pharma, Inc.; MedImmune, Inc.; Meiji Seika Kaisha, Ltd.; Merck; MoonLake; Nimbus; Novartis; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi Genzyme; Sun Pharmaceutical Industries, Ltd.; Takeda; Tarsus; UCB; Ventyx

Alan Irvine, MD

Professor of Dermatology
Trinity College Dublin
Dublin, Ireland

Disclosures

Alan Irvine, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Aslan; Connect Biopharma; Eli Lilly and Company; LEO Pharma, Inc.; Novartis; Pfizer, Inc.; RAPT Therapeutics; Regeneron Pharmaceuticals, Inc.; Sanofi; UCB
Speaker or member of speakers bureau for: AbbVie, Inc.; Almirall S.A.; Eli Lilly and Company; Janssen; Kenvue; Regeneron Pharmaceuticals, Inc.; Sanofi
Research funding from: Regeneron Pharmaceuticals, Inc.

Editor

Marinella Calle, PhD, CMPP

Medical Education Director, WebMD Global, LLC

Disclosures

Marinella Calle, PhD, CMPP, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Established and Emerging Therapies for Moderate-to-Severe Atopic Dermatitis: The Data in Context

Authors: Stephan Weidinger, MD, PhD; Melinda Gooderham, MD, MSc, FRCP; Alan Irvine, MDFaculty and Disclosures

CPD Released: 11/8/2023

Valid for credit through: 11/8/2024, 11:59 PM EST

processing....

Transcripción en español

Download the pdf.

Download Now

« Return to: Established and Emerging Therapies for Moderate-to-Severe Atopic Dermatitis: The Data in Context

CPD

Established and Emerging Therapies for Moderate-to-Severe Atopic Dermatitis: The Data in Context

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Stephan Weidinger, MD, PhD

Melinda Gooderham, MD, MSc, FRCP

Alan Irvine, MD

Editor

Marinella Calle, PhD, CMPP

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Established and Emerging Therapies for Moderate-to-Severe Atopic Dermatitis: The Data in Context

Transcripción en español

PDF Downloads

Transcript Downloads